No Data
No Data
No Data
No Data
No Data
BeiGene (NASDAQ:BGNE) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Simply Wall St12:41 ET
BeiGene reports 2023 annual results, with revenue surging 82.13% to 17.423 billion yuan
According to the Zhitong Finance App, BeiGene (688235.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 17.423 billion yuan, a year-on-year increase of 82.13%; net loss attributable to shareholders of listed companies narrowed sharply to 6.716 billion yuan. Baiyueze, a BTK inhibitor independently developed by the company, has been approved for multiple indications in 70 markets including the United States, China, the European Union, the United Kingdom, Canada, Australia, South Korea and Switzerland. It has established an extensive clinical development layout around the world, and has enrolled more than 5,000 subjects in 29 countries and regions. Momoetsusawa
Zhitong FinanceApr 26 09:19 ET
BeiGene Releases “2023 Responsible Business and Sustainability” Report, Announces Global Progress
The 2023 annual report details the company's achievements in sustainability and future plans in Beijing, China; Cambridge, MA; and Basel, Switzerland, April 26, 2024/PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology innovation company, today released the “2023 Responsible Business and Sustainability” report, which highlights the company's strategy, progress made with current goals, and how to achieve more in the future Positive new goals. In the report
PR NewswireApr 26 06:00 ET
百濟神州:2023年度報告
Futu NewsApr 25 06:00 ET · Announcements
Express News | Beigene : Bernstein Cuts Target Price to $152 From $161
ReutersApr 25 05:49 ET
BeiGene (BGNE) Receives a Hold From Bernstein
TipRanksApr 25 03:45 ET
No Data
No Data
SpyderCall : Very valuable info as usual. Thanks for the hard work.
shintaka1168 : こんな情報を配信してくれるなんて、おどろきました。これからもチェックしようと思います